Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Eva M, Guerra"'
Autor:
María Jesús Rubio, Aránzazu Manzano, Luis Miguel de Sande, Purificación Estévez-García, María del Mar Gordon, Diego Soto de Prado, Blanca Hernando Fernández de Aranguiz, Eva M. Guerra-Alia, Anna Carbó-Bagué, Ignacio Romero, Miguel Corbellas, Alba González-Haba, Carlos E. Robles-Barraza, Jerónimo Martínez-García, Antonio González-Martín
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian cancer. Nevertheless, there is currently limited information regarding this t
Externí odkaz:
https://doaj.org/article/39144675c87243c3ade5b788dbad20d1
Autor:
Mansoor R. Mirza, Antonio González‐Martín, Whitney S. Graybill, David M. O’Malley, Lydia Gaba, Oi Wah Stephanie Yap, Eva M. Guerra, Peter G. Rose, Jean‐François Baurain, Sharad A. Ghamande, Hannelore Denys, Emily Prendergast, Carmela Pisano, Philippe Follana, Klaus Baumann, Paula M. Calvert, Jacob Korach, Yong Li, Izabela A. Malinowska, Divya Gupta, Bradley J. Monk
Publikováno v:
CANCER
Background: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c5da21c2393f06a49b3747604165ac
https://doi.org/10.1002/cncr.34706
https://doi.org/10.1002/cncr.34706
Autor:
Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Coline Montégut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alía, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Rémi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard
Publikováno v:
European Journal of Cancer. 181:42-52
BACKGROUND: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80fe5d4fe19ac187d577cd72e0adfc98
https://doi.org/10.1016/j.ejca.2022.11.029
https://doi.org/10.1016/j.ejca.2022.11.029
Publikováno v:
Consumer Behavior in Tourism and Hospitality. 18:66-80
Purpose Place identity refers to the combination of physical setting, social interactions, emotions and associated meanings. This research paper aims to broaden knowledge about boutique concepts and to examine the role of advertisement types suited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::898e4a2134ff1f442e5898d4c1191c99
https://doi.org/10.1108/cbth-05-2022-0121
https://doi.org/10.1108/cbth-05-2022-0121
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron-Hay, Isabelle Ray-Coquard, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva M. Guerra Alia, Ulus A. Sanli, Steven Bird, Robert Orlowski, Jodi McKenzie, Chinyere Okpara, Gianmaria Barresi, Domenica Lorusso
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ffdf649fcef8434e9d4e758715149a
https://hdl.handle.net/10281/411355
https://hdl.handle.net/10281/411355
Publikováno v:
Marketing by Contingency in the Time of COVID-19 ISBN: 9781003300694
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3ebac1fbc926663c3c8d786a90d5ec8
https://doi.org/10.1201/9781003300694-9
https://doi.org/10.1201/9781003300694-9
Autor:
Krishnansu S, Tewari, Bradley J, Monk, Ignace, Vergote, Austin, Miller, Andreia C, de Melo, Hee-Seung, Kim, Yong Man, Kim, Alla, Lisyanskaya, Vanessa, Samouëlian, Domenica, Lorusso, Fernanda, Damian, Chih-Long, Chang, Evgeniy A, Gotovkin, Shunji, Takahashi, Daniella, Ramone, Joanna, Pikiel, Beata, Maćkowiak-Matejczyk, Eva M, Guerra Alía, Nicoletta, Colombo, Yulia, Makarova, Danny, Rischin, Stephanie, Lheureux, Kosei, Hasegawa, Keiichi, Fujiwara, Jingjin, Li, Shaheda, Jamil, Vladimir, Jankovic, Chieh-I, Chen, Frank, Seebach, David M, Weinreich, George D, Yancopoulos, Israel, Lowy, Melissa, Mathias, Matthew G, Fury, Ana, Oaknin, Rachna T, Shroff
Publikováno v:
Obstetrical & Gynecological Survey. 77:348-350
Background: Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61b695632bb95081113f9be0c7c4b18
https://doi.org/10.1097/01.ogx.0000834600.51705.68
https://doi.org/10.1097/01.ogx.0000834600.51705.68
Autor:
Vicky, Makker, Nicoletta, Colombo, Antonio, Casado Herráez, Alessandro D, Santin, Emeline, Colomba, David S, Miller, Keiichi, Fujiwara, Sandro, Pignata, Sally, Baron-Hay, Isabelle, Ray-Coquard, Ronnie, Shapira-Frommer, Kimio, Ushijima, Jun, Sakata, Kan, Yonemori, Yong Man, Kim, Eva M, Guerra, Ulus A, Sanli, Mary M, McCormack, Alan D, Smith, Stephen, Keefe, Steven, Bird, Lea, Dutta, Robert J, Orlowski, Domenica, Lorusso, Lynne, Knowles
BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previousl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bf5a23a6784e2b36d308838a72a533
http://hdl.handle.net/10281/346556
http://hdl.handle.net/10281/346556
Autor:
Vicky Makker, Nicoletta Colombo, Alessandro Santin, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Isabelle Laure Ray-Coquard, Yong Man Kim, Eva M. Guerra, Jie Huang, Gianmaria Barresi, Jodi McKenzie, Domenica Lorusso
Publikováno v:
Journal of Clinical Oncology. 40:5587-5587
5587 Background: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro had significant PFS and overall survival benefits, and improved objective response rate vs TPC in pts with aEC following systemic platinum-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf4920d6c4d83797b9f93a2fbd72c2e6
https://doi.org/10.1200/jco.2022.40.16_suppl.5587
https://doi.org/10.1200/jco.2022.40.16_suppl.5587